Aralez Pharmaceuticals Inc.
ARLZ
ARLZ was delisted on the 20th of August, 2018.
95 hedge funds and large institutions have $107M invested in Aralez Pharmaceuticals Inc. in 2016 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 26 increasing their positions, 22 reducing their positions, and 26 closing their positions.
262% more call options, than puts
Call options by funds: $1.34M | Put options by funds: $371K
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
19% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 26
18% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 22
6% more funds holding
Funds holding: 90 → 95 (+5)
1% less capital invested
Capital invested by funds: $108M → $107M (-$582K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$10.1M |
| 2 |
PCM
PAR Capital Management
Boston,
Massachusetts
|
+$3.91M |
| 3 |
JAM
JW Asset Management
Miami Beach,
Florida
|
+$3.4M |
| 4 |
HVC
Healthcare Value Capital
Woodcliff Lake,
New Jersey
|
+$1.79M |
| 5 |
KCM
Kingstown Capital Management
New York
|
+$1.54M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$4.88M |
| 2 |
State Street
Boston,
Massachusetts
|
-$2.81M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$2.26M |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$1.83M |
| 5 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
-$1.76M |
ARLZ Hedge Fund Activity: Q2 2016 in Review
95 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Aralez Pharmaceuticals Inc. (ARLZ) for Q2 2016, worth a combined $107M — down 0.54% from $108M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new ARLZ positions and 26 closed out — a net gain of 5 holders — while 26 added to existing stakes and 22 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $10.1M. The largest seller was BlackRock Fund Advisors, exiting entirely with an estimated $4.88M sold.
- 95 institutional investors held Aralez Pharmaceuticals Inc. (ARLZ) as of Q2 2016, up from 90 in Q1 2016.
- Funds reported $107M of Aralez Pharmaceuticals Inc. stock for Q2 2016, down 0.54% quarter-over-quarter.
- 31 funds opened new Aralez Pharmaceuticals Inc. positions in Q2 2016 and 26 closed out, a net change of +5 holders.
- The largest Aralez Pharmaceuticals Inc. buyer in Q2 2016 was Armistice Capital, an estimated $10.1M added.
- The largest Aralez Pharmaceuticals Inc. seller in Q2 2016 was BlackRock Fund Advisors, an estimated $4.88M sold.
Based on aggregated 13F filings for Q2 2016.